Joanna Perła-Kaján

Dr. Joanna Perła-Kaján

Department of Biochemistry and Biotechnology, University of Life Sciences in Poznań, Poznań, Wielkopolskie, Poland
orcid
"... la science a une grande beauté" M. Skłodowska-Curie

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2007 in Amino Acids
Verified
Journal Article
Closed access
PDF file
Joanna Perła-KajánJoanna Perła-Kaján
Joanna Perła-Kaján
TTT. Twardowski
T. Twardowski
Hieronim JakubowskiHieronim Jakubowski
Hieronim Jakubowski

1 June 2004 in Stroke
Verified
Journal Article
Closed access
PDF file
AUAnetta Undas
Anetta Undas
Joanna Perła-KajánJoanna Perła-Kaján
Joanna Perła-Kaján
MŁMariusz Łacinski
Mariusz Łacinski
WTWiesław Trzeciak
Wiesław Trzeciak
RKRadosław Kaźmierski
Radosław Kaźmierski
Hieronim JakubowskiHieronim Jakubowski
Hieronim Jakubowski
Background and Purpose— Homocysteine (Hcy)-thiolactone mediates protein N-homocysteinylation in humans. Protein N-linked Hcy comprises a major pool of Hcy in human blood, greater that the “total” Hcy pool. N-homocysteinylated proteins are structurally different, compared with native proteins, and are thus likely to be recognized as neoself antigens and induce an autoimmune response. This study was undertaken to provide evidence for anti– N ε-Hcy-Lys-protein antibody and to examine associations between the antibody level, Hcy, and stroke in humans. Methods— ELISA was used to quantify anti– N ε-Hcy-Lys-protein antibodies in human serum. Results— We found that autoantibodies that specifically recognize N ε-Hcy-Lys epitope on Hcy-containing proteins occur in humans. Serum levels of anti– N ε-Hcy-Lys-protein autoantibodies positively correlate with plasma total Hcy levels, but not with plasma cysteine or methionine levels. In a group of exclusively male patients with stroke, mean level of anti– N ε-Hcy-Lys-protein autoantibodies was ≈50% higher than in a group of healthy subjects. Conclusion— These findings support a hypothesis that N ε-Hcy-Lys-protein is a neoself antigen, which may contribute to immune activation, an important modulator of atherogenesis.

9 February 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Hieronim JakubowskiHieronim Jakubowski
Hieronim Jakubowski
Joanna Perła-KajánJoanna Perła-Kaján
Joanna Perła-Kaján
RFRichard H. Finnell
Richard H. Finnell
RCRobert M. Cabrera
Robert M. Cabrera
HWHong Wang
Hong Wang
DSDiana M. Shih
Diana M. Shih
Genetic disorders of homocysteine (Hcy) or folate metabolism or high‐methionine diets elevate plasma Hcy and its atherogenic metabolite Hcy‐thiolac‐tone. In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine ς‐synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications. In mouse models, dietary or genetic hyperhomocysteinemia results in liver or brain pathological changes and accelerates atherosclerosis. Hcy‐thiolactone has the ability to form isopeptide bonds with protein lysine residues, which generates modified proteins (A‐Hcy‐protein) with autoimmunogenic and prothrombotic properties. Our aim was to determine how A –Hcy‐protein levels are affected by genetic or nutritional disorders in Hcy or folate metabolism in mice. We found that plasma A‐Hcy‐protein was elevated 10‐fold in mice fed a high‐methionine diet compared with the animals fed a normal commercial diet. We also found that inactivation of Cbs, Mthfr , or the proton‐coupled folate transporter (Pcft) gene resulted in a 10‐to 30‐fold increase in plasma or serum AHcy‐protein levels. Liver AHcy‐protein was elevated 3.4‐fold in severely and 11‐fold in extremely hyperhomocysteinemic Cbs‐deficient mice, 3.6‐fold in severely hyperhomocysteinemic Pcft mice, but was not elevated in mildly hyperhomocysteinemic Mthfr‐deficient animals, suggesting that mice have a capacity to prevent accumulation of A‐Hcy‐protein in their organs. These findings provide evidence that A ‐Hcy‐protein is an important metabolite associated with Hcy pathophysiology in the mouse.—Jakubowski, H.,Peria‐Kajan, J., Finnell, R.H., Cabrera, R.M., Wang, H., Gupta, S., Kruger, W.D., Kraus, J.P., Shih, D.M. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein A‐homocysteinylation in mice. FASEB J. 23, 1721–1727 (2009)

Verified
Journal Article
Open access
PDF file
Joanna Perła-KajánJoanna Perła-Kaján
Joanna Perła-Kaján
Hieronim JakubowskiHieronim Jakubowski
Hieronim Jakubowski
Hyperhomocysteinemia (HHcy) exerts a wide range of biological effects and is associated with a number of diseases, including cardiovascular disease, dementia, neural tube defects, and cancer. Although mechanisms of HHcy toxicity are not fully uncovered, there has been a significant progress in their understanding. The picture emerging from the studies of homocysteine (Hcy) metabolism and pathophysiology is a complex one, as Hcy and its metabolites affect biomolecules and processes in a tissue- and sex-specific manner. Because of their connection to one carbon metabolism and editing mechanisms in protein biosynthesis, Hcy and its metabolites impair epigenetic control of gene expression mediated by DNA methylation, histone modifications, and non-coding RNA, which underlies the pathology of human disease. In this review we summarize the recent evidence showing that epigenetic dysregulation of gene expression, mediated by changes in DNA methylation and histone N-homocysteinylation, is a pathogenic consequence of HHcy in many human diseases. These findings provide new insights into the mechanisms of human disease induced by Hcy and its metabolites, and suggest therapeutic targets for the prevention and/or treatment.

29 May 2012 in Amino Acids
Verified
Journal Article
Closed access
PDF file
Joanna Perła-KajánJoanna Perła-Kaján
Joanna Perła-Kaján
Hieronim JakubowskiHieronim Jakubowski
Hieronim Jakubowski

30 October 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Joanna Perła-KajánJoanna Perła-Kaján
Joanna Perła-Kaján
Hieronim JakubowskiHieronim Jakubowski
Hieronim Jakubowski
Genetic or nutritional disorders in homocysteine (Hcy) or folate metabolism elevate plasma Hcy‐thiolactone and lead to vascular and/or brain pathologies. Hcy‐thiolactone has the ability to form isopeptide bonds with protein lysine residues, which generates N ‐Hcy‐protein with autoimmunogenic and prothrombotic properties. Paraoxonase (PON1), carried on high‐density lipoproteins (HDLs) in the blood, hydrolyzes Hcy‐thiolactone and protects against the accumulation of N ‐Hcy‐protein in vitro. To determine its role in vivo, we studied how natural variation in Hcy‐thiolactonase activity of PON1 affects plasma N‐ Hcy‐protein levels in cystathionine ß‐synthase‐deficient patients ( n =28). We found that plasma N ‐Hcy‐protein was negatively correlated with serum Hcy‐thiolactonase activity ( r =‐0.43, P =0.01), i.e. , the higher the Hcythiolactonase activity, the lower N ‐Hcy protein levels. This relation was faithfully replicated in vitro in experiments with radiolabeled Hcy‐thiolactone. We also found that enzymatic activities of the PON1 protein measured with artificial substrates correlated less strongly ( r =‐0.36, P =0.025 for paraoxonase activity) or did not correlate at all (phenylacetate hydrolase and TBLase activities) with plasma N ‐Hcy protein. These findings provide evidence that the Hcy‐thiolactonase activity of PON1 is a determinant of plasma N ‐Hcy‐protein levels and that Hcy‐thiolactonase/PON1 protects proteins against N ‐homocysteinylation in vivo, a novel mechanism likely to contribute to atheroprotective roles of HDL in humans.—Perla‐Kaján, J., Jakubowski, H. Paraoxonase 1 protects against protein N ‐homocysteinylation in humans. FASEB J. 24, 931–936 (2010). www.fasebj.org